# Peptide Oligonucleotide CDMO Market > Peptide and Oligonucleotide CDMO Market Research Report: Size, Share, Trend Analysis By Types (Peptides, Oligonucleotides, Conjugates), By Applications (Pharmaceuticals, Diagnostics, Cosmetics), By Synthesis Route (Solid-phase Synthesis, Solution-phase Synthesis, Automated Synthesis), By Scale (Preclinical, Clinical, Commercial) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 15.8% - **2022:** $ 5.82 Billion - **2023:** $ 6.74 Billion - **2035:** $ 39.19 Billion - **Key Players:** Lonza (CH), WuXi AppTec (CN), Boehringer Ingelheim (DE), Sartorius (DE), Thermo Fisher Scientific(US), CordenPharma (DE), PeptiDream (JP), AstraZeneca (GB), Evonik Industries (DE) **Report ID:** MRFR/HC/39039-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/peptide-oligonucleotide-cdmo-market-41086 --- ## Market Summary ## **Global Peptide and Oligonucleotide CDMO Market Overview** As per MRFR analysis, the Peptide and Oligonucleotide CDMO Market Size was estimated at 5.82 (USD Billion) in 2022.  The Peptide and Oligonucleotide CDMO Market Industry is expected to grow from 6.74(USD Billion) in 2023 to 25.25 (USD Billion) by 2032. The Peptide and Oligonucleotide CDMO Market CAGR (growth rate) is expected to be around 15.8% during the forecast period (2024 - 2032). ### **Key Peptide and Oligonucleotide CDMO Market Trends Highlighted** The Peptide and Oligonucleotide CDMO Market stands to benefit as pharmaceutical and biotechnology markets continue to grow. There is an increasing trend among pharmaceutical companies to depend on CDMOs in order to cut costs, speed up drug development, and make use of the CDMO's skillset. This market is also fuelled by the increasing number of chronic diseases and the advent of personalized medicine, which in turn creates the need for complex peptides and oligonucleotides. One of the market advancements is the utilization of enhanced technologies such as gene editing and RNA interference that make drug development faster and even more efficient. At this time, the market is gaining momentum towards cost-cutting and efficiency in the manufacturing processes, which boosts the use of continuous manufacturing and automation. Apart from this, the peaking demand for biologics and varying biosimilars also add to the growth of the market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Peptide and Oligonucleotide CDMO Market Drivers** ### Advancements in Gene and Cell Therapies Drive Market Growth The growing prevalence of chronic diseases and the increasing demand for personalized medicine are key factors driving the growth of the Peptide and Oligonucleotide CDMO Market Industry. Gene and cell therapies hold immense promise for treating a wide range of diseases, including cancer, genetic disorders, and neurodegenerative diseases. Peptides and oligonucleotides play a crucial role in these therapies, serving as building blocks for gene editing tools, targeted drug delivery systems, and immunotherapies.The advancements in gene and cell therapies have created a surge in demand for Peptide And Oligonucleotide Cdmo services as companies seek specialized expertise and infrastructure to develop and manufacture these complex therapies. The increasing number of clinical trials and regulatory approvals for gene and cell therapies is expected to further fuel the growth of the Peptide and Oligonucleotide CDMO Market Industry in the coming years. ### Technological Advancements Enhance Efficiency and Reduce Manufacturing Costs The Peptide and Oligonucleotide CDMO Market Industry is witnessing rapid technological advancements that are transforming the manufacturing processes of peptides and oligonucleotides. Automation, artificial intelligence (AI), and machine learning (ML) are being increasingly adopted by Cdmo providers to streamline operations, improve efficiency, and reduce manufacturing costs. These technologies enable real-time monitoring and control of manufacturing processes, reducing the risk of errors and ensuring consistent product quality.Additionally, the use of advanced analytical techniques and high-throughput screening platforms accelerates the development and characterization of peptides and oligonucleotides, further contributing to cost reduction and faster time-to-market. ### Growing Focus on Biologics and Biosimilars Expands Market Opportunities The pharmaceutical industry is witnessing a shift towards biologics and biosimilars, driven by their efficacy and specificity in treating complex diseases. Peptides and oligonucleotides are essential components of many biologics and biosimilars, and the growing demand for these therapies is creating significant opportunities for the Peptide and Oligonucleotide CDMO Market Industry. Cdmo providers are expanding their capabilities to cater to the unique requirements of biologics and biosimilars manufacturing, including specialized expertise in cell culture, fermentation, and purification processes.The increasing number of biosimilar approvals and the growing adoption of biologics in emerging markets are expected to drive the demand for Peptide And Oligonucleotide Cdmo services in the coming years. ## **Peptide and Oligonucleotide CDMO Market Segment Insights** ### **Peptide and Oligonucleotide CDMO Market Type Insights  ** The Peptide and Oligonucleotide CDMO Market is segmented by Type into Peptides, Oligonucleotides, and Conjugates. Peptides are a type of biomolecule composed of two or more amino acids linked by peptide bonds. They are essential components of cells and play a crucial role in various biological processes, such as hormone regulation, immune response, and cell signaling. In the Peptide and Oligonucleotide CDMO Market, peptides are primarily used for therapeutic purposes, particularly in the development of drugs for treating chronic diseases such as cancer and diabetes.The global peptide market is projected to reach USD 24.3 billion by 2024, exhibiting a CAGR of 8.5% during the forecast period (2023-2024). Oligonucleotides are short, single-stranded DNA or RNA molecules. They are used in various applications, including gene therapy, diagnostics, and drug development. In the Peptide and Oligonucleotide CDMO Market, oligonucleotides are primarily used for antisense therapy, which involves targeting specific genes to inhibit their expression. The global oligonucleotide market is expected to grow significantly in the coming years, driven by the increasing demand for personalized medicine and the development of new therapeutic modalities.Conjugates are molecules that combine peptides or oligonucleotides with other molecules, such as proteins or antibodies. They are designed to improve the stability, delivery, and efficacy of therapeutic agents. In the Peptide and Oligonucleotide CDMO Market, conjugates are gaining increasing attention as they offer the potential to overcome the challenges associated with traditional drug delivery approaches. The global conjugate market is anticipated to witness substantial growth in the future, driven by the development of novel drug delivery technologies and the increasing prevalence of chronic diseases.Overall, the Type segment of the Peptide and Oligonucleotide CDMO Market is highly dynamic and evolving. The increasing demand for personalized medicine, the development of new therapeutic modalities, and the technological advancements in drug delivery are driving the growth of this market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Peptide and Oligonucleotide CDMO Market Application Insights  ** The Peptide and Oligonucleotide CDMO Market is segmented by application into Pharmaceuticals, Diagnostics, and Cosmetics. The Pharmaceuticals segment held the largest market share in 2023, owing to the increasing demand for peptide and oligonucleotide-based therapeutics for the treatment of various diseases such as cancer, diabetes, and autoimmune disorders. The Diagnostics segment is expected to grow at a significant CAGR during the forecast period, driven by the rising demand for personalized medicine and the development of new diagnostic technologies.The Cosmetics segment is expected to witness steady growth, driven by the increasing use of peptides and oligonucleotides in anti-aging and skin care products. ### **Peptide and Oligonucleotide CDMO Market Synthesis Route Insights  ** Synthesis Route segments the Peptide and Oligonucleotide CDMO Market into Solid-phase Synthesis, Solution-phase Synthesis, and Automated Synthesis. Among these, Solid-phase Synthesis held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period. This is attributed to the increased adoption of solid-phase synthesis due to its advantages, such as higher yields, purity, and scalability. Solution-phase Synthesis is expected to witness the fastest growth rate during the forecast period due to its simplicity and cost-effectiveness.Automated Synthesis is gaining popularity due to its ability to reduce labor costs and improve efficiency. ### **Peptide and Oligonucleotide CDMO Market Scale Insights  ** The Peptide and Oligonucleotide CDMO Market is segmented by scale into preclinical, clinical, and commercial. The clinical segment held the market share in 2023, owing to the increasing number of clinical trials for new drugs and therapies. The preclinical segment is expected to grow at the highest CAGR during the forecast period due to the rising demand for preclinical studies to assess the safety and efficacy of new drug candidates. The commercial segment is expected to account for a significant share of the market in 2032 as more drugs and therapies are approved for commercial use. ### **Peptide and Oligonucleotide CDMO Market Regional Insights  ** The Peptide and Oligonucleotide CDMO Market is segmented into North America, Europe, APAC, South America, and MEA. North America is the largest regional segment, accounting for over 40% of the global market in 2023. Europe is the second largest regional segment, followed by APAC. The APAC region is expected to grow at the highest CAGR during the forecast period, due to the increasing demand for peptides and oligonucleotides in the region. The growth of the Peptide and Oligonucleotide CDMO Market is driven by several factors, including the increasing demand for peptides and oligonucleotides in the pharmaceutical and biotechnology industries, the rising prevalence of chronic diseases, and the growing adoption of personalized medicine.The market is also expected to benefit from the increasing number of government initiatives to support the development of new peptide and oligonucleotide-based therapies. The Peptide and Oligonucleotide CDMO Market is highly competitive, with a number of major players operating in the market. These players include Thermo Fisher Scientific, Lonza, Bachem, and PeptiDream. The market is also characterized by a number of emerging players, who are offering innovative peptide and oligonucleotide-based products and services. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Peptide and Oligonucleotide CDMO Market Key Players And Competitive Insights** Major players in the Peptide and Oligonucleotide CDMO Market industry are focusing on expanding their product portfolio and geographical reach. They are also investing in research and development to develop new and innovative products. Leading Peptide and Oligonucleotide CDMO Market players are adopting various strategies such as mergers and acquisitions, partnerships, and collaborations to gain a competitive edge in the market. The Peptide and Oligonucleotide CDMO Market development is driven by factors such as increasing demand for peptide and oligonucleotide therapies, growing prevalence of chronic diseases, and technological advancements. The competitive landscape of the Peptide and Oligonucleotide CDMO Market is characterized by the presence of both established and emerging players.A leading company in the Peptide and Oligonucleotide CDMO Market is Thermo Fisher Scientific. The company offers a wide range of peptide and oligonucleotide synthesis services, as well as analytical and purification services. Thermo Fisher Scientific has a global presence and a strong customer base. The company is focused on providing high-quality products and services to its customers. Thermo Fisher Scientific is also investing in research and development to develop new and innovative products.A competitor company in the Peptide and Oligonucleotide CDMO Market is GeneCust. The company offers a range of peptide and oligonucleotide synthesis services, as well as analytical and purification services. GeneCust has a strong presence in the Asia-Pacific region and is expanding its global reach. The company is focused on providing cost-effective products and services to its customers. GeneCust is also investing in research and development to develop new and innovative products. ### **Key Companies in the Peptide and Oligonucleotide CDMO Market Include** ## **Peptide and Oligonucleotide CDMO Market Industry Developments** The Peptide and Oligonucleotide CDMO Market is projected to reach USD 25.25 billion by 2032, exhibiting a CAGR of 15.8% during the forecast period. Key factors driving market growth include increasing demand for personalized medicine, rising prevalence of chronic diseases, and advancements in gene editing technologies.Recent news developments include: In 2023, Thermo Fisher Scientific acquired PeproTech, a leading manufacturer of peptides and proteins, to strengthen its position in the CDMO market. In 2024, Lonza announced plans to invest CHF 1 billion in its Visp, Switzerland site to expand its CDMO capabilities for peptides and oligonucleotides. In 2025, Catalent acquired Paragon Bioservices, a provider of gene therapy and viral vector CDMO services, to enhance its offerings in the growing gene therapy market.These developments underscore the increasing demand for CDMO services in the peptide and oligonucleotide market, driven by the growing complexity and scale of drug development projects. ## **Peptide and Oligonucleotide CDMO Market Segmentation Insights** ### **Peptide and Oligonucleotide CDMO Market Type Outlook** ### **Peptide and Oligonucleotide CDMO Market Application Outlook** ### **Peptide and Oligonucleotide CDMO Market Synthesis Route Outlook** ### **Peptide and Oligonucleotide CDMO Market Scale Outlook** ### **Peptide and Oligonucleotide CDMO Market Regional Outlook** ## Market Drivers ### Regulatory Support for Biologics The evolving regulatory landscape is providing substantial support for the development of biologics, including peptides and oligonucleotides, thereby impacting the Peptide and Oligonucleotide CDMO Market. Regulatory agencies are increasingly recognizing the therapeutic potential of these compounds and are streamlining approval processes. This supportive environment encourages pharmaceutical companies to invest in the development of peptide and oligonucleotide-based therapies. Recent regulatory initiatives aimed at expediting the review of biologics are likely to enhance the attractiveness of these therapies. As a result, CDMOs are positioned to play a critical role in navigating the regulatory complexities, ensuring compliance, and facilitating the timely market entry of innovative products. ### Growing Investment in Biotechnology The surge in investment within the biotechnology sector is a crucial driver for the Peptide and Oligonucleotide CDMO Market. Venture capital and private equity funding have been directed towards biotechnology firms focusing on peptide and oligonucleotide therapeutics. This influx of capital is facilitating research and development activities, enabling companies to explore new therapeutic avenues. Recent statistics reveal that biotechnology investments have reached unprecedented levels, indicating a robust interest in innovative drug development. As biotechnology firms seek to leverage the capabilities of CDMOs for efficient manufacturing processes, the Peptide and Oligonucleotide CDMO Market is poised for significant expansion, driven by this financial momentum. ### Rising Demand for Targeted Therapies The increasing demand for targeted therapies is reshaping the landscape of the Peptide and Oligonucleotide CDMO Market. Patients and healthcare providers are increasingly favoring treatments that offer precision and reduced side effects. Peptides and oligonucleotides are particularly well-suited for targeted therapies due to their ability to interact specifically with biological targets. Market analysis suggests that the shift towards personalized medicine is driving pharmaceutical companies to invest in the development of these therapies. Consequently, CDMOs specializing in peptide and oligonucleotide production are becoming vital players in the market, as they provide the necessary infrastructure and expertise to meet this growing demand. ### Increasing Prevalence of Chronic Diseases The rising incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is a pivotal driver for the Peptide and Oligonucleotide CDMO Market. As these conditions become more prevalent, there is a corresponding demand for innovative therapeutic solutions, including peptide and oligonucleotide-based drugs. According to recent data, the global burden of chronic diseases is expected to increase, necessitating advanced treatment options. This trend compels pharmaceutical companies to collaborate with contract development and manufacturing organizations (CDMOs) to expedite the development and production of these specialized therapies. Consequently, the Peptide and Oligonucleotide CDMO Market is likely to experience substantial growth as it caters to the urgent need for effective treatments. ### Advancements in Biopharmaceutical Research The ongoing advancements in biopharmaceutical research are significantly influencing the Peptide and Oligonucleotide CDMO Market. Innovations in drug discovery and development methodologies, particularly in the fields of genomics and proteomics, are leading to the identification of novel therapeutic targets. This evolution is fostering an environment where peptides and oligonucleotides are increasingly recognized for their therapeutic potential. Market data indicates that the biopharmaceutical sector is projected to expand, with a notable increase in the number of peptide and oligonucleotide-based drugs entering clinical trials. As a result, CDMOs are becoming essential partners in the development process, providing the necessary expertise and resources to bring these innovative therapies to market. ## Future Outlook The Peptide and Oligonucleotide CDMO Market is projected to grow at a 15.8% CAGR from 2025 to 2035, driven by increasing demand for personalized medicine and advancements in biomanufacturing technologies. **New opportunities:** - Expansion into emerging markets with tailored peptide therapies. Investment in automated synthesis platforms for cost efficiency. Development of novel oligonucleotide delivery systems for targeted therapies. By 2035, the market is poised for robust growth, reflecting evolving therapeutic needs and technological advancements. ## Segment Insights ### By Type: Peptides (Largest) vs. Oligonucleotides (Fastest-Growing) In the Peptide and Oligonucleotide CDMO market, Peptides hold the largest market share, benefiting from their established applications in pharmaceuticals, especially in therapeutics for chronic diseases and oncology. Peptides have been widely adopted due to their efficacy, lower side effect profiles, and the increasing prevalence of conditions treatable with peptide-based therapies. In contrast, Oligonucleotides are seeing rapid growth as they gain recognition for their role in gene therapy and personalized medicine, positioning themselves as a critical player in the evolving market landscape. The growth trends within this segment are driven by advancements in technology and an increasing focus on biopharmaceutical development. The ongoing research into gene editing techniques and a rise in funding for genetic therapies are accelerating the adoption of Oligonucleotides. Additionally, the market is experiencing heightened interest in personalized medicine, leading to a surge in demand for tailored therapeutic options, particularly in the Oligonucleotide sector. As a result, while Peptides remain dominant, Oligonucleotides are emerging as a key growth driver in the CDMO space. Peptides (Dominant) vs. Oligonucleotides (Emerging) Peptides are characterized by their high stability, ease of synthesis, and wide range of applications in the biopharmaceutical sector. They are increasingly utilized in drug development due to their specificity and ability to interact with biological targets effectively. The market for peptides is mature, yet continuously innovating, as new methods in synthesis and purification enhance their production efficiency. On the other hand, Oligonucleotides are emerging as a pivotal technology in therapeutic science, primarily due to advancements in RNA-based therapies, such as siRNA and antisense oligonucleotides. Their ability to directly target specific genes offers extraordinary potential for treating genetic disorders and cancers, causing a shift towards personalized and precise medical strategies. ### By Application: Pharmaceuticals (Largest) vs. Diagnostics (Fastest-Growing) In the Peptide and Oligonucleotide CDMO market, the Pharmaceuticals application holds the largest share, driven by the continuous demand for innovative therapeutic solutions. This segment encompasses a range of applications including drug development and [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937), making it a critical area for the growth of CDMO services. Diagnostics is witnessing rapid growth, fueled by advancements in biotechnology and the increasing necessity for precision medicine, reflecting a shift toward predictive diagnostics and biomarker discovery. Pharmaceuticals: Dominant vs. Diagnostics: Emerging The Pharmaceuticals application remains dominant in the Peptide and Oligonucleotide CDMO market, characterized by a robust pipeline of biologics and specialty drugs. Companies focus on leveraging peptides and oligonucleotides to develop targeted therapies, often requiring complex manufacturing processes and stringent quality controls. In contrast, the Diagnostics application is emerging rapidly, benefiting from innovations in genetic testing and personalized diagnostics. This segment emphasizes the need for high-throughput production capabilities and rapid turnaround times, which are essential for successfully addressing the evolving demands in healthcare and enabling timely decision-making in clinical settings. ### By Synthesis Route: Solid-phase Synthesis (Largest) vs. Automated Synthesis (Fastest-Growing) In the Peptide and Oligonucleotide CDMO Market, Solid-phase Synthesis holds the largest market share due to its established methodology and efficacy in producing high-quality peptides. This segment continues to be favored for its scalability and efficiency, particularly in large-scale productions. Solution-phase Synthesis, while also significant, accounts for a smaller share as it often involves longer processing times and higher resource requirements. Automated Synthesis is emerging rapidly, driven by advancements in technology and increased demand for high-throughput capabilities. Solid-phase Synthesis (Dominant) vs. Automated Synthesis (Emerging) Solid-phase Synthesis is predominantly utilized in the Peptide and Oligonucleotide CDMO Market, valued for its straightforward process and efficiency in handling complex peptide sequences. This synthesis method stands out for its ability to streamline production with minimal side reactions, making it the go-to choice for large-scale manufacturing. On the other hand, Automated Synthesis represents an emerging trend, leveraging innovative technology to enhance productivity and reduce manual labor. As regulatory demands increase and the need for rapid delivery of oligonucleotides grows, Automated Synthesis is becoming increasingly significant, offering flexibility and reliability that align with modern pharmaceutical needs. ### By Scale: Commercial (Largest) vs. Preclinical (Fastest-Growing) In the Peptide and Oligonucleotide CDMO Market, the commercial scale segment currently dominates market share, signifying the established players and their ability to meet extensive manufacturing demands. The preclinical segment, in contrast, is experiencing rapid growth, fueled by an increasing number of startups focusing on innovative therapeutic solutions. This shift reflects changing priorities in pharmaceutical developments and a strong pipeline of projects awaiting progress into clinical stages. The growth trends within these segments are driven by a surge in R&D investments aimed at developing novel therapeutics, particularly in the fields of oncology and rare diseases. Regulatory advancements and the heightened emphasis on personalized medicine further accelerate the pace for preclinical research. As the pharmaceutical industry embraces the integrative capabilities of peptides and oligonucleotides, a broader acceptance and demand for commercial scale production is projected, augmenting competition among CDMOs. Commercial (Dominant) vs. Preclinical (Emerging) The commercial scale segment of the Peptide and Oligonucleotide CDMO Market showcases its dominance, characterized by established manufacturing processes and a dependable supply chain. Companies at this scale possess the necessary infrastructure and expertise to handle large-scale production efficiently. Conversely, the preclinical segment emerges as a crucial area of growth, with many biotech companies leveraging cutting-edge technology to accelerate drug development timelines. This segment is characterized by agility and innovation, with numerous startups entering the market to explore novel therapeutic applications. The demand for flexible manufacturing capabilities and personalized treatments positions preclinical as a promising sector for CDMOs aiming to enter their manufacturing phase rapidly, thus serving the evolving needs of pharmaceutical developers. ## Regional Market Share Analysis The Peptide and Oligonucleotide CDMO Market is segmented into North America, Europe, APAC, South America, and MEA. North America is the largest regional segment, accounting for over 40% of the global market in 2023. Europe is the second largest regional segment, followed by APAC. The APAC region is expected to grow at the highest CAGR during the forecast period, due to the increasing demand for peptides and oligonucleotides in the region. The growth of the Peptide and Oligonucleotide CDMO Market is driven by several factors, including the increasing demand for peptides and oligonucleotides in the pharmaceutical and biotechnology industries, the rising prevalence of chronic diseases, and the growing adoption of personalized medicine.The market is also expected to benefit from the increasing number of government initiatives to support the development of new peptide and oligonucleotide-based therapies. The Peptide and Oligonucleotide CDMO Market is highly competitive, with a number of major players operating in the market. These players include Thermo Fisher Scientific, Lonza, Bachem, and PeptiDream. The market is also characterized by a number of emerging players, who are offering innovative peptide and oligonucleotide-based products and services. ## Competitive Benchmarking Major players in the Peptide and Oligonucleotide CDMO Market industry are focusing on expanding their product portfolio and geographical reach. They are also investing in research and development to develop new and innovative products. Leading Peptide and Oligonucleotide CDMO Market players are adopting various strategies such as mergers and acquisitions, partnerships, and collaborations to gain a competitive edge in the market. The Peptide and Oligonucleotide CDMO Market development is driven by factors such as increasing demand for peptide and oligonucleotide therapies, growing prevalence of chronic diseases, and technological advancements. The competitive landscape of the Peptide and Oligonucleotide CDMO Market is characterized by the presence of both established and emerging players.A leading company in the Peptide and Oligonucleotide CDMO Market is Thermo Fisher Scientific. The company offers a wide range of peptide and oligonucleotide synthesis services, as well as analytical and purification services. Thermo Fisher Scientific has a global presence and a strong customer base. The company is focused on providing high-quality products and services to its customers. Thermo Fisher Scientific is also investing in research and development to develop new and innovative products.A competitor company in the Peptide and Oligonucleotide CDMO Market is GeneCust. The company offers a range of peptide and oligonucleotide synthesis services, as well as analytical and purification services. GeneCust has a strong presence in the Asia-Pacific region and is expanding its global reach. The company is focused on providing cost-effective products and services to its customers. GeneCust is also investing in research and development to develop new and innovative products. ## Recent News & Developments The Peptide and Oligonucleotide CDMO Market is projected to reach USD 25.25 billion by 2035, exhibiting a CAGR of 15.8% during the forecast period. Key factors driving market growth include increasing demand for personalized medicine, rising prevalence of chronic diseases, and advancements in gene editing technologies.Recent news developments include: In 2023, Thermo Fisher Scientific acquired PeproTech, a leading manufacturer of peptides and proteins, to strengthen its position in the CDMO market. In 2024, Lonza announced plans to invest CHF 1 billion in its Visp, Switzerland site to expand its CDMO capabilities for peptides and oligonucleotides. In 2025, Catalent acquired Paragon Bioservices, a provider of gene therapy and viral vector CDMO services, to enhance its offerings in the growing gene therapy market.These developments underscore the increasing demand for CDMO services in the peptide and oligonucleotide market, driven by the growing complexity and scale of drug development projects. ## Report Scope | Report Attribute/Metric | Details | | --- | --- | | Market Size 2022 | 5.82(USD Billion) | | Market Size 2023 | 6.74(USD Billion) | | Market Size 2035 | 25.25(USD Billion) | | Compound Annual Growth Rate (CAGR) | 15.8% (2025 - 2035) | | Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | Base Year | 2023 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2023 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Jubilant Holdist, Peptide International, CordenPharma International, Peptech, GenScript Biotech, Thermo Fisher Scientific, Catalent, BioSynthesis, Lonza Group, Auspeptides, Piramal Enterprises, Synpeptide Technologies, PolyPeptide Laboratories, Bachem Group, Wuxi AppTec | | Segments Covered | Type, Application, Synthesis Route, Scale, Regional | | Key Market Opportunities | Increased demand for personalized medicine Growing adoption of oligonucleotide therapeutics Advancements in gene editing technologies Expansion of peptide-based drug development Rising prevalence of chronic diseases. | | Key Market Dynamics | Growing demand technological advancements increasing RampD investments strategic partnerships expanding applications | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation for the Peptide and Oligonucleotide CDMO Market in 2035?** A: The projected market valuation for the Peptide and Oligonucleotide CDMO Market in 2035 is 39.19 USD Billion. **Q: What was the market valuation for the Peptide and Oligonucleotide CDMO Market in 2024?** A: The market valuation for the Peptide and Oligonucleotide CDMO Market in 2024 was 7.805 USD Billion. **Q: What is the expected CAGR for the Peptide and Oligonucleotide CDMO Market from 2025 to 2035?** A: The expected CAGR for the Peptide and Oligonucleotide CDMO Market during the forecast period 2025 - 2035 is 15.8%. **Q: Which companies are considered key players in the Peptide and Oligonucleotide CDMO Market?** A: Key players in the Peptide and Oligonucleotide CDMO Market include Lonza, WuXi AppTec, Boehringer Ingelheim, Sartorius, and Thermo Fisher Scientific. **Q: What are the projected valuations for the Peptide segment by 2035?** A: The projected valuation for the Peptide segment by 2035 is expected to reach 18.5 USD Billion. **Q: How does the market for Oligonucleotides compare to that of Peptides in 2035?** A: By 2035, the market for Oligonucleotides is projected to reach 12.5 USD Billion, indicating a substantial growth compared to the Peptide segment. **Q: What is the expected market size for the Clinical scale segment by 2035?** A: The expected market size for the Clinical scale segment by 2035 is projected to be 12.5 USD Billion. **Q: What synthesis route is anticipated to dominate the Peptide and Oligonucleotide CDMO Market by 2035?** A: Automated Synthesis is anticipated to dominate the market, with a projected valuation of 16.69 USD Billion by 2035. **Q: What applications are driving growth in the Peptide and Oligonucleotide CDMO Market?** A: The Pharmaceuticals application is driving growth, with a projected valuation of 18.5 USD Billion by 2035. **Q: What is the projected valuation for the Commercial scale segment by 2035?** A: The projected valuation for the Commercial scale segment by 2035 is expected to reach 19.2 USD Billion. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/peptide-oligonucleotide-cdmo-market-41086*